Neurodegenerative diseases are one of the most prominent pathologies that affect the nervous system. They are characterized by progressive disintegration of different parts of NS and unknown etiology. Up to date there are non-effective treatments for them and only in some cases, palliative drugs are available alleviating partially and temporarily some symptoms in patients. It is urgent to discover drugs that delay or stop neurodegeneration, as these diseases have a great impact not only in patients but also in their caregivers and whole society.
Neurodegenerative diseases are classified from the clinical symptoms that the patients have. Thus, among disorders with cognitive deficits the most prevalent one is Alzheimer’s disease with around 20 million of patients.
When motor symptoms are the main clinical feature, Parkinson’s disease is the pathology affects more than 4 million people all over the world. If neuromuscular debilitation and atrophy appear as the main clinical features, amyotrophic lateral sclerosis despite being a rare disease may be consider the representative one. Multiple Sclerosis may be included in this last group of diseases affected around globally 4 million of patients, but until now it has been classified as autoinmmune disease. However it is difficult to establish its origin and many researchers agree that multiple sclerosis is a neurodegenerative disease where olygodendrocytes dead in relapsing remittent or progressive ways.